Clozapine, nimodipine and endosulfan differentially suppress behavioral defects caused by gain-of-function mutations in a two-pore domain K+ channel (UNC-58).

Neuroscience Research
Merve Kasap, Donard S Dwyer

Abstract

Two-pore domain K+ channels (K2Ps) regulate the resting membrane potential in excitable cells and determine ease of depolarization. Gain-of-function (gf) mutations in one of these channels (unc-58) in C. elegans switch it to a Na+ conductance channel and cause tremors, paralysis and other defects. We hypothesized that it should be possible to identify drugs that corrected these defects in unc-58(gf) mutant animals by blocking or modulating the over-active channels. We examined dispersal of animals on food because the absence of effective forward locomotion is the most obvious defect. In addition, we quantified egg release over 24 h. Starting with a known inhibitor of mammalian K2Ps and directed structure-based screening, we evaluated numerous drugs in these assays. Loratadine, which inhibits human KCNK18, significantly improved movement as did methiothepin. We confirmed that endosulfan, a GABA-A receptor antagonist, corrected locomotion in the unc-58(gf) strains. Based on structural similarities to other hits, we found that clozapine, loxapine and amoxapine potently suppressed abnormal phenotypes. Curiously, nimodipine, a Ca++-channel blocker, dramatically improved movement and egg laying in unc-58(e665), but not unc-58(n495) a...Continue Reading

References

Dec 1, 1983·Biochemical Pharmacology·A K AgrawalP K Seth
Jan 1, 1996·Annual Review of Entomology·J R Bloomquist
Aug 4, 1998·The EMBO Journal·A J PatelM Lazdunski
Jun 3, 2000·The EMBO Journal·F MaingretE Honoré
Apr 13, 2001·Neuroscience·L SalkoffA Wei
May 18, 2001·Trends in Neurosciences·A J Patel, E Honoré
Nov 16, 2004·Annals of the New York Academy of Sciences·Toru KobayashiKazutaka Ikeda
Feb 3, 2005·British Journal of Pharmacology·Louise E KennardAlistair Mathie
Aug 10, 2006·Psychopharmacology·Shannon G MattaJeffrey M Zirger
Sep 12, 2006·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Dallas R DonohoeDonard S Dwyer
Mar 22, 2007·Nature Reviews. Neuroscience·Eric Honoré
Oct 26, 2007·The Journal of Biological Chemistry·Gawain McCollGordon J Lithgow
Mar 27, 2009·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Rakesh KarmacharyaEdgar A Buttner
Jul 28, 2009·Veterinary Parasitology·Bernadette F ArdelliRoger K Prichard
Apr 16, 2010·Physiological Reviews·Péter Enyedi, Gábor Czirják
Nov 30, 2011·TheScientificWorldJournal·Marios Politis, Clare Loane
Jun 16, 2010·ACS Chemical Neuroscience·Kathrine R WeeksEric J Aamodt
Aug 31, 2013·Journal of Neurology·Corneliu C Luca, Carlos Singer
Jun 28, 2014·European Journal of Pharmacology·J Kyle BrunerMin Li
Jun 29, 2014·EMBO Molecular Medicine·Corinna FriedrichNiels Decher
Jun 9, 2015·Neuropharmacology·Yulin ZhaoRobert W Peoples
Jul 26, 2015·Brain : a Journal of Neurology·Zahi QamhawiNicola Pavese
Feb 8, 2018·Advances in Pharmacology·Jibran Y KhokharAlan I Green

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Related Papers

Anästhesiologie, Intensivmedizin, Notfallmedizin, Schmerztherapie : AINS
M Bräu
Molecular Interventions
Douglas A BaylissEdmund M Talley
© 2021 Meta ULC. All rights reserved